<ѻý>FCR Still an Option in IGHV-Unmutated CLL?ѻý> Gene signature identifies lower-risk group with greater chemoimmunotherapy benefit Oct 08, 2019
<ѻý>First-Line Combo Boosts PFS in Untreated Bladder Cancerѻý> 'Clinically meaningful' trend in OS with atezolizumab-chemotherapy Oct 03, 2019
<ѻý>In Memory of Gerald Chodak, MDѻý> Pioneer of active surveillance for men with low-risk prostate cancer died last week Oct 03, 2019
<ѻý>New Standard in Third-Line Metastatic CRPCѻý> Cabazitaxel tops more anti-androgen in patients with "short-ish" response to abiraterone or enzalutamide Oct 01, 2019
<ѻý>Novel CDK 4/6 Inhibitor Fails in Triple Negative Breast Cancerѻý> Misses primary endpoints but has unexpected key benefit Oct 01, 2019
<ѻý>Neoadjuvant Anti-PD-1 Boosts pCR in TNBCѻý> Favorable trend toward improved event-free survival in preliminary analysis Sep 30, 2019
<ѻý>Trametinib Tx Shows Promise in Tough-to-Treat LGSOCѻý> Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer Sep 30, 2019
<ѻý>Data Support 'Best Drug First' in EGFR-Mutant NSCLCѻý> Six-month survival gain with osimertinib, adding to PFS, safety advantages Sep 29, 2019
<ѻý>CDK 4/6 Inhibitors Boost OS in Advanced Breast Cancerѻý> Abemaciclib, ribociclib should become first-line treatment in HR-positive/HER2-negative disease, expert says Sep 29, 2019
<ѻý>PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Ca?ѻý> PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines Sep 29, 2019
<ѻý>Abemaciclib Offers Hope in HR+/HER2+Breast Cancerѻý> Phase II monarcHER trial shows better PFS with abemaciclib-trastuzumab-fulvestrant Sep 29, 2019
<ѻý>First-Line Combo Boosts PFS in Advanced Ovarian Caѻý> Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup Sep 28, 2019
<ѻý>Advanced HCC Trial Misses OS Endpointѻý> But CheckMate 459 researchers tout "encouraging efficacy and favorable safety profile" Sep 28, 2019
<ѻý>Notable OS Gains with Dual Immunotherapy in Advanced NSCLCѻý> Secondary analysis of CheckMate 227 brings more good news for nivolumab-ipilimumab combo Sep 28, 2019
<ѻý>BCG Vax: A Shot Against Lung Cancer in Native Populations?ѻý> 60-year follow-up data from a vaccine trial found surprising results Sep 25, 2019
<ѻý>Ibrutinib's Cardiotoxicity Comes Into Focusѻý> Study identifies new cardiac events linked to so-called targeted therapy Sep 25, 2019
<ѻý>How Often Does MRI Miss the Mark in Prostate Ca?ѻý> Retrospective study finds 21% of patients with prostate cancer pathology did not have ROI on MRI Sep 25, 2019
<ѻý>Red Cell Distribution Width Strongly Predicts Hip Fractureѻý> Simple way to identify at-risk patients Sep 24, 2019
<ѻý>Wires or RFID Tags in Breast Cancer Excision?ѻý> Women like the less obtrusive method, but small study doesn't quite settle question of whether there's a tradeoff Sep 24, 2019
<ѻý>ASTRO Unveils First RT Guideline for Pancreatic Cancerѻý> Radiation's role in pancreatic cancer is "controversial," says guideline author Sep 23, 2019
<ѻý>H. Pylori Found in Sleeve Gastrectomy Specimensѻý> Incidental findings can have important clinical implications in obese patients Sep 23, 2019
<ѻý>Tx Deintensification Wins in Head and Neck Cancer, But ...ѻý> Only against another less-intensive approach in HPV-positive disease Sep 18, 2019
<ѻý>Could Mom's Anemia Hurt Baby's Brain?ѻý> Association study suggests an increased risk, though still quite small Sep 18, 2019
<ѻý>Gandalf the Grey, the Wizard of Omaha, and Prostate Cancerѻý> High-profile celebs and low-risk disease Sep 18, 2019
<ѻý>Post-Immunotherapy SBRT Boosts Outcomes in Advanced NSCLCѻý> Increased systemic response rate, disease control rate, and PFS in phase II trial Sep 17, 2019
<ѻý>Consider PSA Before Adding ADT to Salvage Radiationѻý> Men with levels below 0.6 ng/mL show no benefit, at risk of other-cause mortality Sep 16, 2019
<ѻý>Medical Marijuana Overdose Sends Man to ERѻý> Case report highlights risks of high-strength THC products in patients' hands Sep 12, 2019
<ѻý>Good News, Bad News for CRISPR Gene Editing for HIV Cureѻý> "Bigger story for the gene-editing field than the HIV field" Sep 11, 2019
<ѻý>Anti-PD-1/L1 for NSCLC Sparks Talk of the 'C' Wordѻý> Unprecedented survival at 3 and 5 years, but investigators reluctant to say "cure" Sep 10, 2019
<ѻý>'Dirtier' Drugs Step Aside in RET-Positive NSCLCѻý> Over two-thirds of patients respond to selective RET inhibitor Sep 09, 2019
<ѻý>TMB in Lung Cancer: 'Not Ready for Prime Time'ѻý> No association between tumor mutational burden and outcomes in three trials Sep 09, 2019
<ѻý>The Legacy of Henry Lynch, MDѻý> Earlier this summer the legendary researcher passed, his contributions to cancer research are immeasurable Sep 01, 2019
<ѻý>Good News on Nipple-Sparing Breast Surgeryѻý> Korean study examined recurrence rates Aug 30, 2019
<ѻý>Peter Fonda’s Lung Cancer Battleѻý> Farewell, Easy Rider: legendary actor dead at 79 Aug 29, 2019
<ѻý>Mystery! The Vanishing Prostate Tumorѻý> Do cancers really disappear spontaneously? Or are they just eluding us? Aug 23, 2019
<ѻý>Olivia Newton-John's Stage 4 Cancer Cannabis Managementѻý> The singer and actress updates fans on her battle, but can marijuana help? Aug 22, 2019
<ѻý>Total Chemo Dose Still Matters in Breast Cancerѻý> Worse survival with cumulative dose Aug 20, 2019
<ѻý>When Medicare Stops Covering a Test Without Warningѻý> Why didn't someone tell me, asks Hans Duvefelt, MD Aug 20, 2019
<ѻý>Newer Prostate Cancer Agents Not Free of Heart Riskѻý> Patients with three or more cardiac conditions were at highest risk of early death Aug 14, 2019